NASDAQ:RGNX - Regenxbio Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Regenxbio Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $40.47 -1.29 (-3.09 %) (As of 12/11/2019 04:00 PM ET) Add Compare Today's Range$40.08Now: $40.47▼$42.5950-Day Range$34.72MA: $39.54▼$44.9152-Week Range$30.38Now: $40.47▼$63.21Volume336,437 shsAverage Volume556,810 shsMarket Capitalization$1.49 billionP/E Ratio17.00Dividend YieldN/ABeta0.86 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RGNX Previous Symbol CUSIPN/A CIK1590877 Webhttp://www.regenxbio.com/ Phone240-552-8181Debt Debt-to-Equity Ratio0.01 Current Ratio11.49 Quick Ratio11.49Price-To-Earnings Trailing P/E Ratio17.00 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$218.51 million Price / Sales6.82 Cash Flow$2.32 per share Price / Cash Flow17.42 Book Value$14.20 per share Price / Book2.85Profitability EPS (Most Recent Fiscal Year)$2.38 Net Income$99.94 million Net Margins-99.57% Return on Equity-18.74% Return on Assets-17.47%Miscellaneous Employees192 Outstanding Shares36,807,000Market Cap$1.49 billion Next Earnings Date2/26/2020 (Estimated) OptionableOptionable Receive RGNX News and Ratings via Email Sign-up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:RGNX Rates by TradingView Regenxbio (NASDAQ:RGNX) Frequently Asked Questions What is Regenxbio's stock symbol? Regenxbio trades on the NASDAQ under the ticker symbol "RGNX." How were Regenxbio's earnings last quarter? Regenxbio Inc (NASDAQ:RGNX) posted its quarterly earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.91) by $0.03. The biotechnology company had revenue of $14.70 million for the quarter, compared to analysts' expectations of $7.46 million. Regenxbio had a negative return on equity of 18.74% and a negative net margin of 99.57%. The business's revenue for the quarter was up 177.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.56) EPS. View Regenxbio's Earnings History. When is Regenxbio's next earnings date? Regenxbio is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Regenxbio. What price target have analysts set for RGNX? 7 brokers have issued twelve-month target prices for Regenxbio's shares. Their forecasts range from $37.00 to $150.00. On average, they anticipate Regenxbio's share price to reach $82.17 in the next year. This suggests a possible upside of 103.0% from the stock's current price. View Analyst Price Targets for Regenxbio. What is the consensus analysts' recommendation for Regenxbio? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Regenxbio. What are Wall Street analysts saying about Regenxbio stock? Here are some recent quotes from research analysts about Regenxbio stock: 1. According to Zacks Investment Research, "REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. " (10/26/2019) 2. Chardan Capital analysts commented, "We note Sarepta Therapeutics (unrated) may be relevant for that theme. The IP discussion began by REGENXBIO discussing Zolgensma and the agreement with Avexis, a Novartis (unrated) company, where REGENXBIO will receive tiered royalties of 6%, 8%, and 10% on Zolgensma sales of $600 mm, respectively, as well as a milestone payment of $80 mm once Zolgensma reaches $1 bn in aggregate sales." (6/18/2019) Has Regenxbio been receiving favorable news coverage? Headlines about RGNX stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Regenxbio earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Regenxbio. Who are some of Regenxbio's key competitors? Some companies that are related to Regenxbio include Moderna (MRNA), argenx (ARGX), BioNTech (BNTX), bluebird bio (BLUE), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Audentes Therapeutics (BOLD) and Acceleron Pharma (XLRN). What other stocks do shareholders of Regenxbio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), Amarin (AMRN), Exelixis (EXEL), AbbVie (ABBV), Micron Technology (MU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), Square (SQ), Visa (V) and Gilead Sciences (GILD). Who are Regenxbio's key executives? Regenxbio's management team includes the folowing people: Mr. Kenneth T. Mills, CEO, Pres & Director (Age 44)Mr. Vittal K. Vasista, Chief Financial Officer (Age 51)Mr. Curran M. Simpson, Sr. VP of Product Devel. & Chief Technology Officer (Age 57)Dr. Olivier Danos, Chief Scientific Officer (Age 61)Dr. Stephen Yoo, Consultant (Age 41) Who are Regenxbio's major shareholders? Regenxbio's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (6.42%), State Street Corp (5.70%), Voya Investment Management LLC (0.72%), Rhumbline Advisers (0.22%), P.A.W. Capital Corp (0.18%) and California Public Employees Retirement System (0.17%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for Regenxbio. Which institutional investors are selling Regenxbio stock? RGNX stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Russell Investments Group Ltd. and Rhumbline Advisers. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Kenneth T Mills, Olivier Danos, Patrick J Christmas and Vittal Vasista. View Insider Buying and Selling for Regenxbio. Which institutional investors are buying Regenxbio stock? RGNX stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, State of New Jersey Common Pension Fund D, Voya Investment Management LLC, State Street Corp, SG Americas Securities LLC, California Public Employees Retirement System, P.A.W. Capital Corp and Squarepoint Ops LLC. View Insider Buying and Selling for Regenxbio. How do I buy shares of Regenxbio? Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Regenxbio's stock price today? One share of RGNX stock can currently be purchased for approximately $40.47. How big of a company is Regenxbio? Regenxbio has a market capitalization of $1.49 billion and generates $218.51 million in revenue each year. The biotechnology company earns $99.94 million in net income (profit) each year or $2.38 on an earnings per share basis. Regenxbio employs 192 workers across the globe.View Additional Information About Regenxbio. What is Regenxbio's official website? The official website for Regenxbio is http://www.regenxbio.com/. How can I contact Regenxbio? Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected] MarketBeat Community Rating for Regenxbio (NASDAQ RGNX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 338 (Vote Outperform)Underperform Votes: 286 (Vote Underperform)Total Votes: 624MarketBeat's community ratings are surveys of what our community members think about Regenxbio and other stocks. Vote "Outperform" if you believe RGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGNX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/11/2019 by MarketBeat.com StaffFeatured Article: Diversification in Your Portfolio
